REG - MyCelx Tech. Corp. MyCelx Tech. Cp-MYXR - Closure of Restricted Stock Line

Mycelx TechnologiesAnnouncement

11/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250911:nRSK8437Ya&default-theme=true

RNS Number : 8437Y  MyCelx Technologies Corporation  11 September 2025

11 September 2025

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Closure of Restricted Stock Line

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water
and clean air technology company, confirms the closure of its restricted line
of stock will take effect at 8.00 a.m. on 12 September 2025.

 

Application has been made to the London Stock Exchange for the transfer of an
additional 1,380,791 common shares of $0.25 each ("Common Shares") (the
"Additional Shares") from the Company's restricted line of stock with the
ticker MYXR (identified under ISIN USU624551318) (the "Restricted Line") to
the Company's unrestricted line of stock with the ticker MYX (identified under
ISIN US62847T2024) (the "Unrestricted Line").

 

The Additional Shares are constituted of 1,380,791 Common Shares which have
been transferred upon expiry of the restricted period under Regulation S of
the US Securities Act of 1933.

 

Trading in the Company's Restricted Line will cease at 8.00 a.m. on 12
September 2025 and all Common Shares currently trading on the Restricted Line
will from then on continue to trade on the Unrestricted Line. Certificated
holders will also be issued a replacement share certificate, representing
their new holding in unrestricted shares.

 

The Company's issued share capital consists of 24,363,814 Common Shares with
no Common Shares held in treasury. Therefore, the total number of voting
rights in the Company is 24,363,814 which may be used by shareholders as the
denominator for the calculations by which they determine if they are required
to notify their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.

 

From 12 September 2025, all of the 24,363,814 Common Shares will be admitted
to trading on the Unrestricted Line.

 

 

For further information, please contact:

 

 MYCELX Technologies Corporation

 Connie Mixon, CEO                                                      Tel: +1 888 306 6843

 Kim Slayton, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

 Giles Balleny / Callum Davidson (Corporate Finance                     Tel: +44 20 7220 0500

 Jamie Anderson (Corporate Broking)

 Jasper Berry / Michael Johnson (Sales)

 Celicourt Communications (Financial PR)

 Mark Antelme                                                           Tel: +44 20 7770 6424

 Jimmy Lea

 Charlie Denley-Myerson

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLMMATMTJBBBA